07:37 AM EDT, 06/26/2024 (MT Newswires) -- Savara (SVRA) said Wednesday that the phase 3 IMPALA-2 clinical trial assessing the efficacy and safety of Molgramostim in adult patients with autoimmune pulmonary alveolar proteinosis met its primary endpoint.

The trial showed statistically significant improvement in percent predicted diffusing capacity of the lungs for carbon monoxide versus placebo at week 24 and week 48, the company said.

The company also said that Molgramostim was well tolerated and 97% of the patients completed the double-blind treatment through week 48 with no trial drug related adverse events leading to discontinuation.

The company's share price was up over 30% during premarket activity on Wednesday.

Price: 4.9600, Change: +1.16, Percent Change: +30.53